Aetna
Aetna Aetna
Specialty Pharmacy Clinical Policy Bulletins
Aetna Non-Medicare Prescription Drug Plan
Subject: Specialty Quantity Limit Jynarque 2571-H P2022a

Policy:

      I.  PROGRAM DESCRIPTION

          The standard limit is designed to allow a quantity sufficient for
          the most common uses of the medication. The recommended
          dosing parameters for all FDA-approved indications fall within
          the standard limits. Coverage of an additional quantity may be
          reviewed on a case-by-case basis upon request.

 
    II.  COVERED QUANTITIES

 

          Medication

     Standard Limit

      FDA-recommended dosing

  Jynarque Carton
  15mg-15mg tablets

  56 per 28 days

 

  Initial dose is 60 mg orally daily (45mg
  on waking and 15mg 8 hours later).
  Titrate to 90mg daily (60mg on waking
  and 30mg 8 hours later) and then to
  120mg daily (90mg on waking and
  30mg 8 hours later) if tolerated with at
  least weekly intervals between
  titrations. Patients may down-titrate
  based on tolerability.

 

  Co-Administration with Moderate CYP
  3A Inhibitors:
  Reduce dose per below. Consider
  further reductions if patient cannot
  tolerate the reduced dose.
    •    120mg daily: reduce to 60mg
          daily (45mg on waking and 15mg
          8 hours later)
    •    90mg daily: reduce to 45mg
          daily (30mg on waking and 15mg
          8 hours later)
    •    60mg daily: reduce to 30mg daily
          (15mg on waking and 15mg
          8 hours later)

  Jynarque Carton
  30mg-15mg tablets

  56 per 28 days

  Jynarque Carton
  45mg-15mg tablets

  56 per 28 days

  Jynarque Carton
  60mg-30mg tablets

  56 per 28 days

  Jynarque Carton
  90mg-30mg tablets

  56 per 28 days

  Jynarque 30mg
  tablets (30 count bottle)

  30 per 30 days

  Jynarque 15mg
  tablets (30 count bottle)

  60 per 30 days

 


Place of Service:

Outpatient

The above policy is based on the following references:
  1. Jynarque [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; October 2020.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 11, 2023
Aetna
Skip Past Footer Links
Company Information   |   Site Map Aetna.com Home   |   Help   |   Contact Us   |   Search
Web Privacy Statement   |   Legal Statement   |   Privacy Notices   |   Member Disclosure

Back to top